JPS606616A - 血管拡張剤 - Google Patents
血管拡張剤Info
- Publication number
- JPS606616A JPS606616A JP11383283A JP11383283A JPS606616A JP S606616 A JPS606616 A JP S606616A JP 11383283 A JP11383283 A JP 11383283A JP 11383283 A JP11383283 A JP 11383283A JP S606616 A JPS606616 A JP S606616A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- injection
- formula
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124549 vasodilator Drugs 0.000 title claims abstract description 8
- 239000003071 vasodilator agent Substances 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000004020 conductor Substances 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 5
- -1 methoxy, methylamino, dimethylamino, furfurylamino Chemical group 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 abstract 1
- 230000036474 chronotropism Effects 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003212 purines Chemical class 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- 229960002963 ganciclovir Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical class O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000002057 chronotropic effect Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- FAIFWGKDQOGGSP-BEFMGFOSSA-N (2R,3R,4S,5R)-2-(6-amino-6-cyclohexyl-8H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1N=C2C(N)(C3CCCCC3)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O FAIFWGKDQOGGSP-BEFMGFOSSA-N 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11383283A JPS606616A (ja) | 1983-06-24 | 1983-06-24 | 血管拡張剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11383283A JPS606616A (ja) | 1983-06-24 | 1983-06-24 | 血管拡張剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS606616A true JPS606616A (ja) | 1985-01-14 |
| JPH0361646B2 JPH0361646B2 (enrdf_load_stackoverflow) | 1991-09-20 |
Family
ID=14622157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11383283A Granted JPS606616A (ja) | 1983-06-24 | 1983-06-24 | 血管拡張剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS606616A (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597339A1 (fr) * | 1986-04-16 | 1987-10-23 | Bounan Michel | Trois substances a activite antitumorale preparees par dilutions successives d'hormones vegetales de croissance. |
| US4853386A (en) * | 1985-08-17 | 1989-08-01 | Boehringer Mannheim Gmbh | N6 -disubstituted purine derivatives, and pharmaceutical compositions containing them, useful for treating allergic diseases, bronchospastic and bronchoconstrictory conditions |
| US5565566A (en) * | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| JP2016513621A (ja) * | 2013-03-05 | 2016-05-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼの阻害剤 |
-
1983
- 1983-06-24 JP JP11383283A patent/JPS606616A/ja active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853386A (en) * | 1985-08-17 | 1989-08-01 | Boehringer Mannheim Gmbh | N6 -disubstituted purine derivatives, and pharmaceutical compositions containing them, useful for treating allergic diseases, bronchospastic and bronchoconstrictory conditions |
| EP0212535B1 (de) * | 1985-08-17 | 1991-05-29 | Roche Diagnostics GmbH | N6-Disubstituierte Purinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel |
| FR2597339A1 (fr) * | 1986-04-16 | 1987-10-23 | Bounan Michel | Trois substances a activite antitumorale preparees par dilutions successives d'hormones vegetales de croissance. |
| US5565566A (en) * | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| JP2016513621A (ja) * | 2013-03-05 | 2016-05-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼの阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0361646B2 (enrdf_load_stackoverflow) | 1991-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2304770C (en) | A use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds | |
| JPH04504726A (ja) | アナフィラキシーの遅反応性物質に対する拮抗薬としてのリポキシンａ↓４およびその誘導体の使用 | |
| EP0692487A1 (en) | Cholestasis ameliorant | |
| EP3950689A1 (en) | Nucleoside derivative for preventing and treating inflammation and application thereof | |
| CZ20012672A3 (cs) | Lék pro léčbu vysokého krevního tlaku | |
| JPH06234637A (ja) | 腫瘍壊死因子アルファを阻害するためのレフルノミドの使用 | |
| CA2056967A1 (en) | Use of organic compounds | |
| CN1944448B (zh) | 葛根素衍生物及其药物用途 | |
| JPS606616A (ja) | 血管拡張剤 | |
| US4914105A (en) | Anti-cancer compositions for delivering 5-fluorouracil | |
| HU179450B (en) | Process for producing ergoline derivatives | |
| DE2925943A1 (de) | 1-alkadien-2,4-yl-2-hydroxymethyl3,4,5-trihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| JPH04264030A (ja) | 抗喘息剤 | |
| JPS63502180A (ja) | アミノグリコシド ステロイド、それらの製造方法、それらの使用法及びそれらを含有する治療用組成物 | |
| DE69415682T2 (de) | Neue urethan enthaltende aminosteroid verbindungen | |
| DK160558B (da) | N6-substituerede adenosiner, fremstilling og anvendelse af disse, samt farmaceutiske praeparater indeholdende saadanne forbindelser | |
| AU2016294185B2 (en) | Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and therapeutic agent for gynecological disorders using same | |
| WO2005003146A1 (fr) | C-glycosylisoflavones a substituant alkylaminoalcoxyle, leur preparation et leur utilisation | |
| DE2610985A1 (de) | Arzneimittel enthaltend beta-d-1 (6-amino-9h-purin-9-yl)-1-deoxyribofuranuronsaeurederivate | |
| JP3057295B2 (ja) | 心機能回復剤 | |
| CZ86696A3 (en) | Novel oligosaccharide derivatives of 14-aminosteroidal compounds and novel diastereoselective process of aminosteroidal chemistry | |
| DK159454B (da) | N6-substituerede adenosiner samt farmaceutiske praeparater indeholdende saadanne | |
| WO1997044031A1 (fr) | Agent de traitement de l'eczema allergique | |
| JPH06172182A (ja) | エチアンアルデヒドのイミノ誘導体を含む高血圧処置用医薬組成物 | |
| CN104876942B (zh) | 单硝酸异山梨酯半水化合物 |